Goldman Sachs Turns Bullish On Biotech With 'Significant Opportunity'
Portfolio Pulse from Priya Nigam
Goldman Sachs upgraded Quanterix Corp (NASDAQ:QTRX) from Neutral to Buy and raised the price target from $13 to $27. Quanterix, a leader in the neurology diagnostics market, has a strong technology platform in Simoa and could play an important role in the blood-based Alzheimer's diagnostics market.
May 23, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs upgraded Quanterix Corp (QTRX) to Buy and raised the price target to $27, highlighting the company's potential in the Alzheimer's diagnostics market.
Goldman Sachs' upgrade and increased price target for Quanterix Corp (QTRX) indicate a positive outlook for the company. The analyst highlights the company's strong technology platform in Simoa and its potential role in the blood-based Alzheimer's diagnostics market. This news is likely to have a positive short-term impact on QTRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100